Seven Eight Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-19,336
| Closed | -$1.36M | – | 88 |
|
|
2024
Q3 | $1.36M | Buy |
+19,336
| New | +$1.62M | 0.12% | 302 |
|
|
2023
Q4 | – | Sell |
-2,653
| Closed | -$235K | – | 635 |
|
|
2023
Q3 | $235K | Sell |
2,653
-77,146
| -97% | -$6.86M | 0.03% | 541 |
|
|
2023
Q2 | $6.92M | Buy |
79,799
+27,310
| +52% | +$2.57M | 1.14% | 4 |
|
|
2023
Q1 | $5.1M | Buy |
52,489
+49,051
| +1,427% | +$5.09M | 1.06% | 10 |
|
|
2022
Q4 | $356K | Buy |
+3,438
| New | +$323K | 0.09% | 278 |
|
|
2022
Q3 | – | Sell |
-2,588
| Closed | -$214K | – | 495 |
|
|
2022
Q2 | $214K | Sell |
2,588
-54,340
| -95% | -$4.33M | 0.09% | 325 |
|
|
2022
Q1 | $4.39M | Buy |
56,928
+49,474
| +664% | +$4.14M | 0.59% | 39 |
|
|
2021
Q4 | $659K | Sell |
7,454
-36,506
| -83% | -$3.01M | 0.12% | 229 |
|
|
2021
Q3 | $3.4M | Buy |
43,960
+34,500
| +365% | +$2.72M | 0.33% | 90 |
|
|
2021
Q2 | $789K | Buy |
+9,460
| New | +$750K | 0.11% | 321 |
|
|
2020
Q1 | – | Sell |
-20,818
| Closed | -$1.76M | – | 478 |
|
|
2019
Q4 | $1.76M | Sell |
20,818
-15,228
| -42% | -$1.15M | 0.09% | 330 |
|
|
2019
Q3 | $2.43M | Buy |
+36,046
| New | +$2.78M | 0.13% | 241 |
|
|
2019
Q2 | – | Sell |
-8,977
| Closed | -$797K | – | 585 |
|
|
2019
Q1 | $797K | Buy |
+8,977
| New | +$832K | 0.04% | 387 |
|
|
2018
Q4 | – | Sell |
-17,977
| Closed | -$1.74M | – | 546 |
|
|
2018
Q3 | $1.74M | Buy |
17,977
+5,700
| +46% | +$569K | 0.11% | 273 |
|
|
2018
Q2 | $1.16M | Buy |
+12,277
| New | +$1.08M | 0.08% | 266 |
|
|
2017
Q4 | – | Sell |
-2,800
| Closed | -$261K | – | 458 |
|
|
2017
Q3 | $261K | Sell |
2,800
-32,800
| -92% | -$2.9M | 0.03% | 398 |
|
|
2017
Q2 | $3.23M | Buy |
35,600
+33,600
| +1,680% | +$3.06M | 0.46% | 63 |
|
|
2017
Q1 | $176K | Buy |
+2,000
| New | +$178K | 0.03% | 371 |
|
|
2015
Q4 | – | Sell |
-100
| Closed | -$11K | – | 554 |
|
|
2015
Q3 | $11K | Buy |
+100
| New | +$13.4K | 0.01% | 441 |
|
|
2015
Q2 | – | Sell |
-900
| Closed | -$112K | – | 540 |
|
|
2015
Q1 | $112K | Buy |
+900
| New | +$95.4K | 0.19% | 185 |
|
|
2014
Q3 | – | Sell |
-300
| Closed | -$19K | – | 524 |
|
|
2014
Q2 | $19K | Buy |
+300
| New | +$18.1K | 0.02% | 441 |
|
Other funds holding BMRN
EIM
Seven Eight Capital's BMRN Position: Q4 2024 in Review
Seven Eight Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2024, closing a stake of 19,336 shares — an estimated $1.36M sold.
Seven Eight Capital first reported a position in BMRN in Q2 2014 and held it in 21 quarters. The position peaked at $6.92M in Q2 2023. 544 funds tracked by Wall St. Rank hold BMRN as of Q4 2024.
- Seven Eight Capital reported no remaining BioMarin Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
- Seven Eight Capital sold 19,336 BioMarin Pharmaceuticals shares in Q4 2024, an estimated $1.36M.
- Seven Eight Capital first reported a position in BioMarin Pharmaceuticals in Q2 2014 and held it in 21 quarters.
- Seven Eight Capital's BioMarin Pharmaceuticals position peaked at $6.92M in Q2 2023.
- 544 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2024.
Based on Seven Eight Capital's 13F filing for Q4 2024.